Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 11/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 3/20 | 0.50 |
| ▸ | GSTM2 | P28161 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.48 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.48 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4785470 | 0.87 | IDO1 (0.53) | IDO1GSTP1GSTM2MEN1KMT2A | |
| SCHEMBL5244876 | 0.87 | IDO1 (0.60) | IDO1GSTP1GSTM2MEN1KMT2A | |
| SCHEMBL4784084 | 0.82 | IDO1 (0.52) | IDO1GSTP1GSTM2MEN1KMT2A | |
| SCHEMBL5243642 | 0.80 | MYC (0.67) | IDO1GSTP1GSTM2MEN1KMT2A | |
| SCHEMBL7052057 | 0.79 | GSTM2 (0.66) | IDO1GSTP1GSTM2MEN1KMT2A | |
| SCHEMBL5246953 | 0.78 | IDO1 (0.60) | IDO1GSTP1GSTM2MEN1KMT2A | |
| SCHEMBL5281251 | 0.77 | MEN1 (0.51) | IDO1GSTP1GSTM2MEN1KMT2A | |
| SCHEMBL5243120 | 0.77 | KMT2A (0.52) | IDO1GSTP1GSTM2MEN1KMT2A | |
| SCHEMBL4787390 | 0.77 | MYC (0.57) | IDO1GSTP1GSTM2MEN1KMT2A | |
| SCHEMBL5244899 | 0.77 | MYC (0.52) | IDO1GSTP1GSTM2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | claimed |
| WO-2008115259-A2 | DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115259-A2 | DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | IDO1 805/4885GSTP1 2061/4885GSTM2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.